See today's BioWorld Science
To read the full story, subscribe or sign in.
Immuno-oncology

Rise Therapeutics’ R-5780 gains IND clearance from FDA

Jan. 14, 2025
Rise Therapeutics LLC has gained IND clearance from the FDA to initiate a phase I trial of R-5780 in patients with cancer.
BioWorld Science Regulatory Cancer Immuno-oncology FDA IND